HeartSciences' MyoVista wavECGTM Selected To Be Used In Irish Heart Screening Evaluation
Portfolio Pulse from Happy Mohamed
HeartSciences' MyoVista wavECG has been selected by PanaceaFlo Ltd for use in a heart screening evaluation study in Dublin, Ireland. The study aims to establish a cardiovascular risk screening program and integrated care hub pathway. If successful, the program will roll out nationally in Ireland. The initial screening will involve approximately 250 members of the public, including Garda Siochana officers.
August 24, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HeartSciences' MyoVista wavECG has been selected for a heart screening study in Ireland. If successful, this could lead to a national rollout of the program, potentially increasing the demand for MyoVista.
The selection of HeartSciences' MyoVista wavECG for the heart screening study in Ireland indicates recognition of the product's potential. If the study is successful and the program rolls out nationally, it could significantly increase the demand for MyoVista, positively impacting HeartSciences' revenues and stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100